DK1108435T3 - Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel - Google Patents

Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel

Info

Publication number
DK1108435T3
DK1108435T3 DK99938591T DK99938591T DK1108435T3 DK 1108435 T3 DK1108435 T3 DK 1108435T3 DK 99938591 T DK99938591 T DK 99938591T DK 99938591 T DK99938591 T DK 99938591T DK 1108435 T3 DK1108435 T3 DK 1108435T3
Authority
DK
Denmark
Prior art keywords
agents
active ingredient
pancreatitis
receptor antibodies
containing anti
Prior art date
Application number
DK99938591T
Other languages
Danish (da)
English (en)
Inventor
Akihiro Funakoshi
Kyoko Miyasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1108435T3 publication Critical patent/DK1108435T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK99938591T 1998-08-24 1999-08-23 Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel DK1108435T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25179698 1998-08-24
JP5430299 1999-03-02
PCT/JP1999/004533 WO2000010607A1 (fr) 1998-08-24 1999-08-23 Produits preventifs ou therapeutiques de la pancreatite contenant des antagonistes de il-6 comme substance active

Publications (1)

Publication Number Publication Date
DK1108435T3 true DK1108435T3 (da) 2007-02-05

Family

ID=26395047

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99938591T DK1108435T3 (da) 1998-08-24 1999-08-23 Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel

Country Status (11)

Country Link
US (1) US8440196B1 (fr)
EP (1) EP1108435B1 (fr)
JP (1) JP4711507B2 (fr)
AT (1) ATE350060T1 (fr)
AU (1) AU757261B2 (fr)
CA (1) CA2341239C (fr)
DE (1) DE69934698T2 (fr)
DK (1) DK1108435T3 (fr)
ES (1) ES2276525T3 (fr)
PT (1) PT1108435E (fr)
WO (1) WO2000010607A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322216A1 (fr) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique ou préventif pour les maladies liées aux lymphocytes T sensibilisés comprenant l'antagoniste IL-6 en tant qu'ingrédient actif
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4960096B2 (ja) * 2003-09-22 2012-06-27 ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−6の生物学的効果を減じる化合物の使用
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005090405A1 (fr) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Sous-type d'anticorps humanisé contre un récepteur de l'interleukine-6
WO2007043641A1 (fr) 2005-10-14 2007-04-19 Fukuoka University Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
US9981415B2 (en) 2007-09-10 2018-05-29 Ehc Canada, Inc. Method and apparatus for extrusion of thermoplastic handrail
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
CA2728243C (fr) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Inhibiteur de neuro-invasion
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011149051A1 (fr) 2010-05-28 2011-12-01 中外製薬株式会社 Agent améliorant la réponse de lymphocytes t anti-tumoraux
WO2011149046A1 (fr) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Agent thérapeutique contre le cancer du pancréas
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
JPWO2012067150A1 (ja) * 2010-11-16 2014-05-12 三菱化学株式会社 Interleukin−6receptorsubunitbeta蛋白質による脳梗塞の検査方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
JP6117915B2 (ja) 2012-05-21 2017-04-19 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーKorea Research Institute Of Bioscience And Biotechnology ミゾコウジュの抽出物またはその分画物を有効成分として含む、stat3媒介性疾患の予防または治療用医薬組成物
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CA2984255C (fr) 2015-05-07 2023-02-14 Ehc Canada, Inc. Mains courantes composites compactes ayant des proprietes mecaniques ameliorees
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
ES2894684T3 (es) 2015-06-19 2022-02-15 Ehc Canada Inc Método y aparato para la extrusión de pasamanos termoplástico
WO2017147169A1 (fr) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chimioprévention utilisant des formulations à libération contrôlée d'agents anti-interleukine 6, d'analogues ou des métabolites synthétiques de la vitamine a et de métabolites de l'œstradiol
WO2018112237A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de l'il -6 r
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
EP3554541B1 (fr) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du récepteur de chimiokine
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
WO2018183929A1 (fr) 2017-03-30 2018-10-04 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (fr) 2018-01-31 2019-08-08 元一 加藤 Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
EP3947737A2 (fr) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
EP3957324A4 (fr) 2019-04-17 2023-02-08 Hiroshima University Agent thérapeutique pour cancer urologique caractérisé en ce qu'il est administré avec un inhibiteur de il-6 et un inhibiteur de ccr2 en combinaison
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
WO2024126805A1 (fr) 2022-12-15 2024-06-20 Aarhus Universitet Activation synthétique de récepteurs transmembranaires multimères

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 gp130蛋白質に対する抗体
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp gp130蛋白質に対するモノクロ−ナル抗体
JP3525221B2 (ja) 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il-6产生所致疾病的药物组合物
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
AU6038196A (en) 1995-06-07 1996-12-30 Private Biologicals Corporation Compositions and methods of treating il-6 associated disease s

Also Published As

Publication number Publication date
US8440196B1 (en) 2013-05-14
DE69934698T2 (de) 2007-10-04
PT1108435E (pt) 2007-04-30
AU5304999A (en) 2000-03-14
CA2341239A1 (fr) 2000-03-02
EP1108435B1 (fr) 2007-01-03
ES2276525T3 (es) 2007-06-16
WO2000010607A1 (fr) 2000-03-02
CA2341239C (fr) 2011-01-04
ATE350060T1 (de) 2007-01-15
AU757261B2 (en) 2003-02-13
JP4711507B2 (ja) 2011-06-29
EP1108435A4 (fr) 2002-05-08
DE69934698D1 (de) 2007-02-15
EP1108435A1 (fr) 2001-06-20

Similar Documents

Publication Publication Date Title
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
DK1074268T3 (da) IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
AU6420798A (en) A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
CY1108180T1 (el) Προληπτικα ή/και θεραπευτικα για συστημικο ερυθηματωδη λυκο που περιεχουν αντισωμα αντι-il-6 υποδοχεα ως το δραστικο συστατικο
BR9610875A (pt) Modulares rxr seletivos - dimeros e processos para seu uso
DK1037634T3 (da) Oral administrationsform som omfatter en protonpumpeinhibitor (fx pantoprazo)
NO971546D0 (no) Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
CY1111825T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη
NO995558L (no) Terapeutisk middel for kakeksi
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
DK0733626T3 (da) N-(Benzofurazanyl)-arylsulfonamider og analoger deraf, der kan anvendes som endothelin-receptor-antagonister
WO2002080969A1 (fr) Remedes pour des maladies liees a l'arthrite chronique du nourrisson
NO976074L (no) To- og treverdige småmolekylinhibitorer for selektin
TR199501132A2 (tr) Nörokinin karsitlari (antagonistleri).
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO20022584L (no) Kombinerte midler for behandling av glaukom
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
TR199903065T2 (xx) Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
DK630088A (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
ATE288738T1 (de) Orale zusammensetzung